These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 30315232)

  • 1. Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells.
    Ross DM; Pagani IS; Shanmuganathan N; Kok CH; Seymour JF; Mills AK; Filshie RJ; Arthur CK; Dang P; Saunders VA; Braley J; Yong AS; Yeung DT; White DL; Grigg AP; Schwarer AP; Branford S; Hughes TP;
    Leukemia; 2018 Dec; 32(12):2572-2579. PubMed ID: 30315232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remission.
    Pagani IS; Dang P; Saunders VA; Grose R; Shanmuganathan N; Kok CH; Carne L; Rwodzi Z; Watts S; McLean J; Braley J; Altamura H; Yeung DT; Branford S; Yong ASM; White DL; Hughes TP; Ross DM
    Leukemia; 2020 Apr; 34(4):1052-1061. PubMed ID: 31768016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial.
    Atallah E; Schiffer CA; Radich JP; Weinfurt KP; Zhang MJ; Pinilla-Ibarz J; Kota V; Larson RA; Moore JO; Mauro MJ; Deininger MWN; Thompson JE; Oehler VG; Wadleigh M; Shah NP; Ritchie EK; Silver RT; Cortes J; Lin L; Visotcky A; Baim A; Harrell J; Helton B; Horowitz M; Flynn KE
    JAMA Oncol; 2021 Jan; 7(1):42-50. PubMed ID: 33180106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study.
    Takahashi N; Tauchi T; Kitamura K; Miyamura K; Saburi Y; Hatta Y; Miyata Y; Kobayashi S; Usuki K; Matsumura I; Minami Y; Usui N; Fukuda T; Takada S; Ishikawa M; Fujimaki K; Gomyo H; Sasaki O; Ohishi K; Miyake T; Imai K; Suzushima H; Mitsui H; Togitani K; Kiguchi T; Atsuta Y; Ohtake S; Ohnishi K; Kobayashi Y; Kiyoi H; Miyazaki Y; Naoe T;
    Int J Hematol; 2018 Feb; 107(2):185-193. PubMed ID: 28929332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuation.
    Chomel JC; Bonnet ML; Sorel N; Sloma I; Bennaceur-Griscelli A; Rea D; Legros L; Marfaing-Koka A; Bourhis JH; Ame S; Guerci-Bresler A; Rousselot P; Turhan AG
    Oncotarget; 2016 Jun; 7(23):35293-301. PubMed ID: 27167108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib.
    Stella S; Zammit V; Vitale SR; Pennisi MS; Massimino M; Tirrò E; Forte S; Spitaleri A; Antolino A; Siracusa S; Accurso V; Mannina D; Impera S; Musolino C; Russo S; Malato A; Mineo G; Musso M; Porretto F; Martino B; Di Raimondo F; Manzella L; Vigneri P; Stagno F
    Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31064152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR.
    Ross DM; Branford S; Seymour JF; Schwarer AP; Arthur C; Bartley PA; Slader C; Field C; Dang P; Filshie RJ; Mills AK; Grigg AP; Melo JV; Hughes TP
    Leukemia; 2010 Oct; 24(10):1719-24. PubMed ID: 20811403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.
    Shiseki M; Yoshida C; Takezako N; Ohwada A; Kumagai T; Nishiwaki K; Horikoshi A; Fukuda T; Takano H; Kouzai Y; Tanaka J; Morita S; Sakamoto J; Sakamaki H; Inokuchi K
    Int J Clin Oncol; 2017 Oct; 22(5):972-979. PubMed ID: 28550414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study.
    Shih YT; Cortes JE; Kantarjian HM
    Lancet Haematol; 2019 Aug; 6(8):e398-e408. PubMed ID: 31208943
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Pagani IS; Dang P; Kommers IO; Goyne JM; Nicola M; Saunders VA; Braley J; White DL; Yeung DT; Branford S; Hughes TP; Ross DM
    Haematologica; 2018 Dec; 103(12):2026-2032. PubMed ID: 29976745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new highly sensitive real-time quantitative-PCR method for detection of BCR-ABL1 to monitor minimal residual disease in chronic myeloid leukemia after discontinuation of imatinib.
    Kitamura H; Tabe Y; Ai T; Tsuchiya K; Yuri M; Misawa S; Horii T; Kawaguchi A; Ohsaka A; Kimura S
    PLoS One; 2019; 14(3):e0207170. PubMed ID: 30835732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High Level of CD8
    Kwaśnik P; Zaleska J; Link-Lenczowska D; Zawada M; Wysogląd H; Ochrem B; Bober G; Wasilewska E; Hus I; Szarejko M; Prejzner W; Grzybowska-Izydorczyk O; Klonowska-Szymczyk A; Mędraś E; Kiełbus M; Sacha T; Giannopoulos K
    Cells; 2024 Apr; 13(8):. PubMed ID: 38667336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imatinib discontinuation in chronic myeloid leukaemia patients with undetectable BCR-ABL transcript level: A systematic review and a meta-analysis.
    Campiotti L; Suter MB; Guasti L; Piazza R; Gambacorti-Passerini C; Grandi AM; Squizzato A
    Eur J Cancer; 2017 May; 77():48-56. PubMed ID: 28365527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors.
    D'Adda M; Farina M; Schieppati F; Borlenghi E; Bottelli C; Cerqui E; Ferrari S; Gramegna D; Pagani C; Passi A; Maifredi A; Tucci A; Capucci MA; Ruggeri G; Rossi G
    Cancer; 2019 May; 125(10):1674-1682. PubMed ID: 30707758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?
    Kong JH; Winton EF; Heffner LT; Chen Z; Langston AA; Hill B; Arellano M; El-Rassi F; Kim A; Jillella A; Kota VK; Bodó I; Khoury HJ
    Cancer; 2017 Jul; 123(13):2482-2488. PubMed ID: 28241101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML.
    Branford S; Yeung DT; Ross DM; Prime JA; Field CR; Altamura HK; Yeoman AL; Georgievski J; Jamison BA; Phillis S; Sullivan B; Briggs NE; Hertzberg M; Seymour JF; Reynolds J; Hughes TP
    Blood; 2013 May; 121(19):3818-24. PubMed ID: 23515925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Feasibility of the imatinib stop study in the Japanese clinical setting: delightedly overcome CML expert stop TKI trial (DOMEST Trial).
    Fujisawa S; Ueda Y; Usuki K; Kobayashi H; Kondo E; Doki N; Nakao T; Kanda Y; Kosugi N; Kosugi H; Kumagai T; Harada H; Shikami M; Maeda Y; Sakura T; Inokuchi K; Saito A; Nawa Y; Ogasawara M; Nishida J; Kondo T; Yoshida C; Kuroda H; Tabe Y; Maeda Y; Imajo K; Kojima K; Morita S; Komukai S; Kawaguchi A; Sakamoto J; Kimura S
    Int J Clin Oncol; 2019 Apr; 24(4):445-453. PubMed ID: 30421023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients.
    Nicolini FE; Dulucq S; Boureau L; Cony-Makhoul P; Charbonnier A; Escoffre-Barbe M; Rigal-Huguet F; Coiteux V; Varet B; Dubruille V; Lenain P; Rousselot P; Rea D; Guerci-Bresler A; Legros L; Liu J; Gardembas M; Ianotto JC; Turlure P; Johnson-Ansah H; Martiniuc J; Jardel H; Joly B; Zunic P; Henni T; Villemagne B; Berger MG; Cayssials E; Guilhot F; Larosa F; Guilhot J; Etienne G; Mahon FX
    Clin Cancer Res; 2019 Nov; 25(22):6606-6613. PubMed ID: 31292142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment-free remission with first- and second-generation tyrosine kinase inhibitors.
    Cortes J; Rea D; Lipton JH
    Am J Hematol; 2019 Mar; 94(3):346-357. PubMed ID: 30394563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tyrosine kinase inhibitor discontinuation in the management of chronic myeloid leukemia: a critical review of the current practice.
    Breccia M; Efficace F; Colafigli G; Scalzulli E; Di Prima A; Martelli M; Foà R
    Expert Rev Hematol; 2020 Dec; 13(12):1311-1318. PubMed ID: 33205694
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 22.